Caspofungin Acetate
FDA-approved product (powder, intravenous), marketed as Cancidas, Caspofungin Acetate.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Aspergillosis
- Candidemia
- Candidiasis
- Fungal infectious disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antimycotics for systemic use
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AX04
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA65.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli53.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae57.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Caspofungin Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma51.3% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome50.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency49.5% AI-predicted activityagainst K. pneumoniae7 registered studies
- LetermovirExisting use: Cytomegalovirus infection, Infection, Viral disease49.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Codeine SulfateExisting use: Cough, Drug dependence, Migraine disorder and 2 more48.8% AI-predicted activityagainst K. pneumoniae23 registered studies
- Bromocriptine MesylateExisting use: Acromegaly, Adenoma, Hyperprolactinemia and 4 more48.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- PimecrolimusExisting use: Atopic eczema, Eczematoid dermatitis48.3% AI-predicted activityagainst K. pneumoniae50+ registered studies
- LypressinExisting use: Vasopressin and analogues48.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma48.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more48.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Dolutegravir SodiumExisting use: HIV infection, HIV-1 infection47.9% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Folic AcidExisting use: Acne, Anemia, Anemia (phenotype) and 8 more47.8% AI-predicted activityagainst K. pneumoniae50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)
NCT00717860 · start 2008-08
Registered record
- Registry ID
- NCT00717860
- Conditions
- Fungal Infection
- Interventions
- caspofungin acetate; Comparator: Micafungin sodium
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-08
- Completion
- 2010-07
- Enrolment
- 121
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFungal InfectionInterventioncaspofungin acetate; Comparator: Micafungin sodiumPhasePhase 3Registry statusCompletedAntimycotic Prophylaxis in Pediatric Patients Following Allogeneic Stem Cell Transplantation
NCT01040156 · start 2008-08
Registered record
- Registry ID
- NCT01040156
- Conditions
- Systemic Aspergillosis; Systemic Candidiasis
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2008-08
- Completion
- 2009-12
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSystemic Aspergillosis; Systemic CandidiasisInterventionNot recordedPhaseNot recordedRegistry statusCompletedIsavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
NCT00413218 · start 2007-03-08
Registered record
- Registry ID
- NCT00413218
- Conditions
- Candidiasis, Invasive; Candidemia; Mycoses
- Interventions
- Isavuconazole; Caspofungin; Voriconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2007-03-08
- Completion
- 2015-03-03
- Enrolment
- 450
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCandidiasis, Invasive; Candidemia; MycosesInterventionIsavuconazole; Caspofungin; VoriconazolePhasePhase 3Registry statusCompletedOpen, Pharmacokinetic Study of Caspofungin in Neonates and Infants (0991-058)
NCT00330395 · start 2006-05
Registered record
- Registry ID
- NCT00330395
- Conditions
- Candidiasis
- Interventions
- caspofungin acetate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2006-05
- Completion
- 2006-10
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCandidiasisInterventioncaspofungin acetatePhasePhase 2Registry statusCompletedA Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)
NCT00250432 · start 2006-01
Registered record
- Registry ID
- NCT00250432
- Conditions
- Invasive Candidiasis
- Interventions
- caspofungin acetate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2006-01
- Completion
- 2008-03
- Enrolment
- 204
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInvasive CandidiasisInterventioncaspofungin acetatePhasePhase 3Registry statusCompletedAntimicrobial PK in Infants With Suspected or Confirmed Infection
NCT00491426 · start 2006-01
Registered record
- Registry ID
- NCT00491426
- Conditions
- Infection
- Interventions
- Ampicillin; Metronidazole; Piperacillin/Tazobactam; Acyclovir; Amphotericin B; Ambisome; Anidulafungin; Caspofungin
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2006-01
- Completion
- 2010-11
- Enrolment
- 450
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfectionInterventionAmpicillin; Metronidazole; Piperacillin/Tazobactam; Acyclovir +4 morePhaseNot recordedRegistry statusCompletedCaspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
NCT00110045 · start 2005-02
Registered record
- Registry ID
- NCT00110045
- Conditions
- Cancer
- Interventions
- caspofungin acetate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2005-02
- Completion
- Not recorded
- Enrolment
- 171
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCancerInterventioncaspofungin acetatePhasePhase 2Registry statusCompletedCaspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care Units
NCT00099775 · start 2004-12
Registered record
- Registry ID
- NCT00099775
- Conditions
- Candidiasis
- Interventions
- Caspofungin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2004-12
- Completion
- 2005-09
- Enrolment
- 1,200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCandidiasisInterventionCaspofunginPhasePhase 3Registry statusCompletedStudy of Micafungin in Patients With Invasive Candidiasis or Candidemia
NCT00105144 · start 2004-09
Registered record
- Registry ID
- NCT00105144
- Conditions
- Candidiasis; Candidemia
- Interventions
- Micafungin; Caspofungin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2004-09
- Completion
- 2006-04
- Enrolment
- 611
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCandidiasis; CandidemiaInterventionMicafungin; CaspofunginPhasePhase 3Registry statusCompletedTrial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis
NCT00665639 · start 2004-06
Registered record
- Registry ID
- NCT00665639
- Conditions
- Candidiasis, Oral
- Interventions
- micafungin; caspofungin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2004-06
- Completion
- 2004-12
- Enrolment
- 454
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCandidiasis, OralInterventionmicafungin; caspofunginPhasePhase 3Registry statusCompletedCaspofungin for the Treatment of Non-blood Candida Infections (0991-045)
NCT00083343 · start 2004-05
Registered record
- Registry ID
- NCT00083343
- Conditions
- Candidiasis
- Interventions
- MK0991, caspofungin acetate/Duration of Treatment: variable
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2004-05
- Completion
- 2006-02
- Enrolment
- 48
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCandidiasisInterventionMK0991, caspofungin acetate/Duration of Treatment: variablePhasePhase 2Registry statusCompletedOpen, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)
NCT00292071 · start 2004-05
Registered record
- Registry ID
- NCT00292071
- Conditions
- Fungal Infection
- Interventions
- caspofungin acetate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2004-05
- Completion
- 2006-07
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFungal InfectionInterventioncaspofungin acetatePhasePhase 2Registry statusCompletedDocumented Candida or Aspergillus Infections in Pediatric Patients (0991-043)
NCT00082524 · start 2004-04
Registered record
- Registry ID
- NCT00082524
- Conditions
- Aspergillosis; Candidiasis
- Interventions
- caspofungin acetate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2004-04
- Completion
- 2007-07
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAspergillosis; CandidiasisInterventioncaspofungin acetatePhasePhase 2Registry statusCompletedMK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044)
NCT00082537 · start 2004-04
Registered record
- Registry ID
- NCT00082537
- Conditions
- Neutropenia; Fever
- Interventions
- caspofungin acetate; Comparator: AmBisome
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2004-04
- Completion
- 2006-10
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNeutropenia; FeverInterventioncaspofungin acetate; Comparator: AmBisomePhasePhase 2Registry statusCompletedAcetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection
NCT00388167 · start 2004-03
Registered record
- Registry ID
- NCT00388167
- Conditions
- Candidiasis; Aspergillosis
- Interventions
- Caspofungin
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2004-03
- Completion
- 2008-02
- Enrolment
- 320
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCandidiasis; AspergillosisInterventionCaspofunginPhaseNot recordedRegistry statusCompleted